1

6

8

9

10

11

12

13

15

16

17

FILED CAROL C. LAM United States Attorney 02 DEC 13 AM 11: 36 JOHN B. SCHERLING

Assistant United States Attorney California State Bar No. 122234 880 Front Street, Room 6293 San Diego, California 92101-8893

Telephone: (619) 557-7120

CLERK. U.S. DISTRICT COUL-

aY:

DEPUTY

Attorneys for Plaintiff

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF CALIFORNIA

UNITED STATES OF AMERICA,

Plaintiff,

v.

Undetermined quantities of an article of drug in plastic bottles, each bottle containing 90 capsules, more or less, labeled in

14 part:

(bottle)

(flyer)

(flyer)

"\*\*\* EverCLRTM \*\*\* 90 CAPSULES \*\*\* Manufactured exclusively for: Halo Supply Co., San Diego, CA \*\*\*!

18

and 19

> undetermined quantities of promotional literature, labeling for the article of drug, labeled in part:

22

20

21

23

"\*\*\* Cold & Flu Protection \*\*\* 24 EverCLR is great for managing the herpes viruses \*\*\*"

"\*\*\* HOW TO TAKE EverCLR \*\*\*, "

Defendant.

25

26

27

28

'02 CV . 2450 K (LSP)

Civil No.

COMPLAINT FOR FORFEITURE

For its claim against the defendant article of drug, the United States of America alleges as follows:

I.

This Court has jurisdiction under 28 U.S.C. 1345 and 21 U.S.C. 334.

II.

The article is a drug within the meaning of the Federal Food, Drug, and Cosmetic Act (Act), 21 U.S.C. 321(g)(1)(B), because, as indicated in its labeling, it is intended for use in the cure, mitigation, treatment, or prevention of human disease.

III.

The article is a drug within the meaning of the Act, 21 U.S.C. 321(g)(1), that may not be introduced or delivered for introduction into interstate commerce pursuant to 21 U.S.C. 355(a) because it is a new drug within the meaning of 21 U.S.C. 321(p) and no approval of an application filed pursuant to 21 U.S.C. 355(b) is in effect for such drug.

IV.

The article of drug is misbranded while held for sale after shipment of one or more of its components in interstate commerce, within the meaning of the Act, 21 U.S.C. 352(f)(1), in that its labeling fails to bear adequate directions for use and it is not exempt from such requirement under 21 CFR 201.115 because the article is an unapproved new drug.

٧.

The article of drug, which is in the possession of Halo Supply Company, 7950 Silverton Avenue, Suite 203, and 7940 Silverton Avenue, Suite 210, San Diego, California, or elsewhere within the jurisdic-

tion of this Court, consists in whole or in part of components that 1 were shipped in interstate commerce from outside the State of 2 California. 3 VT. 4 By reason of the foregoing, the article is held illegally within 5 the jurisdiction of this Court and is liable to seizure and condemnation. 7 WHEREFORE, plaintiff requests as follows: 8 That process issue against the article; 9 That all persons having any interest in the article be cited 10 to appear herein and answer the allegations of the complaint; 11 That this Court decree the condemnation and forfeiture of 12 the article and grant plaintiff the costs of this proceeding against 13 the claimant of the article; 14 That the article be disposed of as this Court may direct 15 pursuant to the provisions of the Act; and 16 That plaintiff have such other and further relief as the 5. 17 case may require. 18 DATED: December 13, 2002 CAROL C. LAM 19 United States Attorney 20 JOHN B. SCHERLING 21 Assistant U.S. Attorney 22 Attorneys for Plaintiff United States of America 23 OF COUNSEL: 24 DANIEL TROY Chief Counsel 25 ERIC BLUMBERG Deputy Chief Counsel 26 STEVEN SILVERMAN Associate Chief Counsel 27 U.S. Food and Drug Administration 28

## VERIFICATION

I, Barbara J. Rincon, Compliance Officer of the Food and Drug Administration, United States Department of Health and Human Services, declare under penalty of perjury as provided by 28 U.S.C. 1746, that I have read the foregoing Complaint for Forfeiture and that the information contained therein is true and correct to the best of my knowledge and belief.

DATED: 10 Dec. 2002

BARBARA J. RINCON